Vascular contributions to cognitive impairment, clinical Alzheimer's disease, and dementia in older persons

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 5, 2016, Pages 878-886

  Kapasi, A ^a   Schneider, J A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Dementia; Mixed pathologies; Neuropathology; Vascular

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTERIOLOSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN INJURY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; RISK REDUCTION; VASCULAR AMYLOIDOSIS; WHITE MATTER LESION;

EID: 84954306767     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.12.023     Document Type: Article

References (127)

1. Baumgart M., Snyder H.M., Carrillo M.C., Fazio S., Kim H., Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement. 2015, 11:718-726.
2. Spillantini M.G., Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013, 12:609-622.
3. Bennett D.A., Arnold S.E., Valenzuela M.J., Brayne C., Schneider J.A. Cognitive and social lifestyle: links with neuropathology and cognition in late life. Acta Neuropathol. 2014, 127:137-150.
4. Canobbio I., Abubaker A.A., Visconte C., Torti M., Pula G. Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's disease. Front. Cell. Neurosci. 2015, 9:65.
5. Snyder H.M., Corriveau R.A., Craft S., Faber J.E., Greenberg S.M., Knopman D., Lamb B.T., Montine T.J., Nedergaard M., Schaffer C.B., Schneider J.A., Wellington C., Wilcock D.M., Zipfel G.J., Zlokovic B., Bain L.J., Bosetti F., Galis Z.S., Koroshetz W., Carrillo M.C. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement. 2015, 11:710-717.
6. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
7. Janota C., Lemere C.A., Brito M.A. Dissecting the contribution of vascular alterations and aging to Alzheimer's disease. Mol. Neurobiol. 2015.
8. Venkat P., Chopp M., Chen J. Models and mechanisms of vascular dementia. Exp. Neurol. 2015.
9. Attems J., Jellinger K.A. The overlap between vascular disease and Alzheimer's disease - lessons from pathology. BMC Med. 2014, 12. (206-014-0206-2).
10. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197-2204.
11. Boyle P.P., Yu L.P., Nag S.M.P., Leurgans S.P., Wilson R.P., Bennett D.M., Schneider J.M.M. Cerebral Amyloid Angiopathy and Cognitive Outcomes in Community-based Older Persons 2015, (in press).
12. Schneider J.A. High blood pressure and microinfarcts: a link between vascular risk factors, dementia, and clinical Alzheimer's disease. J. Am. Geriatr. Soc. 2009, 57:2146-2147.
13. Toledo J.B., Arnold S.E., Raible K., Brettschneider J., Xie S.X., Grossman M., Monsell S.E., Kukull W.A., Trojanowski J.Q. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013, 136:2697-2706.
14. Group N. Medical Research Council Cognitive Function and Aging Study, pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001, 357:169-175.
15. White L. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J. Alzheimers Dis. 2009, 18:713-725.
16. Schneider J.A., Bennett D.A. Where vascular meets neurodegenerative disease. Stroke 2010, 41. (S144-6).
17. James B.D., Bennett D.A., Boyle P.A., Leurgans S., Schneider J.A. Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA 2012, 307:1798-1800.
18. Wilcock D.M., Schmitt F.A., Head E. Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome. Biochim. Biophys. Acta 2015.
19. McCarron M.O., Nicoll J.A., Graham D.I. A quartet of Down's syndrome, Alzheimer's disease, cerebral amyloid angiopathy, and cerebral haemorrhage: interacting genetic risk factors. J. Neurol. Neurosurg. Psychiatry 1998, 65:405-406.
20. Sobey C.G., Judkins C.P., Sundararajan V., Phan T.G., Drummond G.R., Srikanth V.K. Risk of major cardiovascular events in people with Down syndrome. PLoS One 2015, 10.
21. Melville C.A., Cooper S.A., McGrother C.W., Thorp C.F., Collacott R. Obesity in adults with Down syndrome: a case-control study. J. Intellect. Disabil. Res. 2005, 49:125-133.
22. Esbensen A.J. Health conditions associated with aging and end of life of adults with Down syndrome. Int. Rev. Res. Ment. Retard. 2010, 39:107-126.
23. de Bruijn R.F., Heeringa J., Wolters F.J., Franco O.H., Stricker B.H., Hofman A., Koudstaal P.J., Ikram M.A. Association between atrial fibrillation and dementia in the general population. JAMA Neurol. 2015, 1-7.
24. Langballe E.M., Ask H., Holmen J., Stordal E., Saltvedt I., Selbaek G., Fikseaunet A., Bergh S., Nafstad P., Tambs K. Alcohol consumption and risk of dementia up to 27 years later in a large, population-based sample: the HUNT study, Norway. Eur. J. Epidemiol. 2015, 30:1049-1056.
25. van Oijen M., de Jong F.J., Witteman J.C., Hofman A., Koudstaal P.J., Breteler M.M. Atherosclerosis and risk for dementia. Ann. Neurol. 2007, 61:403-410.
26. Launer L.J., Ross G.W., Petrovitch H., Masaki K., Foley D., White L.R., Havlik R.J. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 2000, 21:49-55.
27. Petrovitch H., White L.R., Izmirilian G., Ross G.W., Havlik R.J., Markesbery W., Nelson J., Davis D.G., Hardman J., Foley D.J., Launer L.J. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging study. Neurobiol. Aging 2000, 21:57-62.
28. Sparks D.L., Scheff S.W., Liu H., Landers T.M., Coyne C.M., Hunsaker J.C. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J. Neurol. Sci. 1995, 131:162-169.
29. Richardson K., Stephan B.C., Ince P.G., Brayne C., Matthews F.E., Esiri M.M. The neuropathology of vascular disease in the Medical Research Council Cognitive Function And Ageing Study (MRC CFAS). Curr. Alzheimer Res. 2012, 9:687-696.
30. Jayaraman A., Pike C.J. Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. Curr. Diab Rep. 2014, 14. (476-014-0476-2).
31. Arvanitakis Z., Schneider J.A., Wilson R.S., Li Y., Arnold S.E., Wang Z., Bennett D.A. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006, 67:1960-1965.
32. Sonnen J.A., Larson E.B., Brickell K., Crane P.K., Woltjer R., Montine T.J., Craft S. Different patterns of cerebral injury in dementia with or without diabetes. Arch. Neurol. 2009, 66:315-322.
33. Wang L.Y., Larson E.B., Sonnen J.A., Shofer J.B., McCormick W., Bowen J.D., Montine T.J., Li G. Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J. Am. Geriatr. Soc. 2009, 57:1975-1981.
34. Bell R.D., Zlokovic B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 2009, 118:103-113.
35. Mok V., Kim J.S. Prevention and management of cerebral small vessel disease. J. Stroke 2015, 17:111-122.
36. Smith E.E., Schneider J.A., Wardlaw J.M., Greenberg S.M. Cerebral microinfarcts: the invisible lesions. Lancet Neurol. 2012, 11:272-282.
37. de Rotte A.A., Koning W., den Hartog A.G., Bovens S.M., Zwanenburg J.J., Klomp D.W., Pasterkamp G., Moll F.L., Luijten P.R., de Borst G.J., Hendrikse J. 7.0 T MRI detection of cerebral microinfarcts in patients with a symptomatic high-grade carotid artery stenosis. J. Cereb. Blood Flow Metab. 2014, 34:1715-1719.
38. Longstreth W.T. Brain abnormalities in the elderly: frequency and predictors in the United States (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group. J. Neural Transm. Suppl. 1998, 53:9-16.
39. Longstreth W.T., Sonnen J.A., Koepsell T.D., Kukull W.A., Larson E.B., Montine T.J. Associations between microinfarcts and other macroscopic vascular findings on neuropathologic examination in 2 databases. Alzheimer Dis. Assoc. Disord. 2009, 23:291-294.
40. Leys D., Henon H., Mackowiak-Cordoliani M.A., Pasquier F. Poststroke dementia. Lancet Neurol. 2005, 4:752-759.
41. Kokmen E., Whisnant J.P., O'Fallon W.M., Chu C.P., Beard C.M. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology 1996, 46:154-159.
42. Arvanitakis Z., Leurgans S.E., Barnes L.L., Bennett D.A., Schneider J.A. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011, 42:722-727.
43. Buchman A.S., Wilson R.S., Shulman J.M., Leurgans S.E., Schneider J.A., Bennett D.A. Parkinsonism in older adults and its association with adverse health outcomes and neuropathology. J. Gerontol. A Biol. Sci. Med. Seci. 2015.
44. Smith E.E., O'Donnell M., Dagenais G., Lear S.A., Wielgosz A., Sharma M., Poirier P., Stotts G., Black S.E., Strother S., Noseworthy M.D., Benavente O., Modi J., Goyal M., Batool S., Sanchez K., Hill V., McCreary C.R., Frayne R., Islam S., DeJesus J., Rangarajan S., Teo K., Yusuf S., et al. Early cerebral small vessel disease and brain volume, cognition, and gait. Ann. Neurol. 2015, 77:251-261.
45. Qiu C., Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat. Rev. Cardiol. 2015, 12:267-277.
46. Brundel M., de Bresser J., van Dillen J.J., Kappelle L.J., Biessels G.J. Cerebral microinfarcts: a systematic review of neuropathological studies. J. Cereb. Blood Flow Metab. 2012, 32:425-436.
47. Gold G., Giannakopoulos P., Herrmann F.R., Bouras C., Kovari E. Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain 2007, 130:2830-2836.
48. Schneider J.A., Boyle P.A., Arvanitakis Z., Bienias J.L., Bennett D.A. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Ann. Neurol. 2007, 62:59-66.
49. Sonnen J.A., Larson E.B., Haneuse S., Woltjer R., Li G., Crane P.K., Craft S., Montine T.J. Neuropathology in the adult changes in thought study: a review. J. Alzheimers Dis. 2009, 18:703-711.
50. van Veluw S.J., Hilal S., Kuijf H.J., Ikram M.K., Xin X., Yeow T.B., Venketasubramanian N., Biessels G.J., Chen C. Cortical Microinfarcts on 3 T MRI: Clinical Correlates in Memory-clinic Patients, Alzheimers Dement 2015.
51. van Veluw S.J., Jolink W.M., Hendrikse J., Geerlings M.I., Luijten P.R., Biessels G.J., Klijn C.J. Cortical microinfarcts on 7 T MRI in patients with spontaneous intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 2015, 35:1222.
52. Westover M.B., Bianchi M.T., Yang C., Schneider J.A., Greenberg S.M. Estimating cerebral microinfarct burden from autopsy samples. Neurology 2013, 80:1365-1369.
53. Yarchoan M., Xie S.X., Kling M.A., Toledo J.B., Wolk D.A., Lee E.B., Van Deerlin V., Lee V.M., Trojanowski J.Q., Arnold S.E. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 2012, 135:3749-3756.
54. Thal D.R., von Arnim C., Griffin W.S., Yamaguchi H., Mrak R.E., Attems J., Upadhaya A.R. Pathology of clinical and preclinical Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263(Suppl. 2):S137-S145.
55. Gupta A., Iadecola C. Impaired Abeta clearance: a potential link between atherosclerosis and Alzheimer's disease. Front. Aging Neurosci. 2015, 7:115.
56. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997, 277:813-817.
57. Dolan H., Crain B., Troncoso J., Resnick S.M., Zonderman A.B., Obrien R.J. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Ann. Neurol. 2010, 68:231-240.
58. Honig L.S., Kukull W., Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005, 64:494-500.
59. Beach T.G., Wilson J.R., Sue L.I., Newell A., Poston M., Cisneros R., Pandya Y., Esh C., Connor D.J., Sabbagh M., Walker D.G., Roher A.E. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol. 2007, 113:13-21.
60. Roher A.E., Esh C., Kokjohn T.A., Kalback W., Luehrs D.C., Seward J.D., Sue L.I., Beach T.G. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2055-2062.
61. Huang K.L., Lin K.J., Ho M.Y., Chang Y.J., Chang C.H., Wey S.P., Hsieh C.J., Yen T.C., Hsiao I.T., Lee T.H. Amyloid deposition after cerebral hypoperfusion: evidenced on [(18)F]AV-45 positron emission tomography. J. Neurol. Sci. 2012, 319:124-129.
62. Keable A., Fenna K., Yuen H.M., Johnston D.A., Smyth N.R., Smith C., Salman R.A., Samarasekera N., Nicoll J.A., Attems J., Kalaria R.N., Weller R.O., Carare R.O. Deposition of amyloid beta in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy. Biochim. Biophys. Acta 2015.
63. Arvanitakis Z., Leurgans S.E., Wang Z., Wilson R.S., Bennett D.A., Schneider J.A. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann. Neurol. 2011, 69:320-327.
64. Ellis R.J., Olichney J.M., Thal L.J., Mirra S.S., Morris J.C., Beekly D., Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996, 46:1592-1596.
65. Haglund M., Passant U., Sjobeck M., Ghebremedhin E., Englund E. Cerebral amyloid angiopathy and cortical microinfarcts as putative substrates of vascular dementia. Int. J. Geriatr. Psychiatry 2006, 21:681-687.
66. Esiri M., Chance S., Joachim C., Warden D., Smallwood A., Sloan C., Christie S., Wilcock G., Smith A.D. Cerebral amyloid angiopathy, subcortical white matter disease and dementia: literature review and study in OPTIMA. Brain Pathol. 2015, 25:51-62.
67. Pfeifer L.A., White L.R., Ross G.W., Petrovitch H., Launer L.J. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002, 58:1629-1634.
68. Charidimou A., Shakeshaft C., Werring D.J. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front. Neurol. 2012, 3:133.
69. Grinberg L.T., Thal D.R. Vascular pathology in the aged human brain. Acta Neuropathol. 2010, 119:277-290.
70. Yip A.G., McKee A.C., Green R.C., Wells J., Young H., Cupples L.A., Farrer L.A. APOE, vascular pathology, and the AD brain. Neurology 2005, 65:259-265.
71. Thal D.R., Ghebremedhin E., Orantes M., Wiestler O.D. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J. Neuropathol. Exp. Neurol. 2003, 62:1287-1301.
72. Barnes L.L., Leurgans S., Aggarwal N.T., Shah R.C., Arvanitakis Z., James B.D., Buchman A.S., Bennett D.A., Schneider J.A. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology 2015, 85:528-534.
73. Chou S.H., Shulman J.M., Keenan B.T., Secor E.A., Buchman A.S., Schneider J., Bennett D.A., De Jager P.L. Genetic susceptibility for ischemic infarction and arteriolosclerosis based on neuropathologic evaluations. Cerebrovasc. Dis. 2013, 36:181-188.
74. Yates P.A., Villemagne V.L., Ellis K.A., Desmond P.M., Masters C.L., Rowe C.C. Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Front. Neurol. 2014, 4:205.
75. Smith E.E., Nandigam K.R., Chen Y.W., Jeng J., Salat D., Halpin A., Frosch M., Wendell L., Fazen L., Rosand J., Viswanathan A., Greenberg S.M. MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage. Stroke 2010, 41:1933-1938.
76. Benedictus M.R., Goos J.D., Binnewijzend M.A., Muller M., Barkhof F., Scheltens P., Prins N.D., van der Flier W.M. Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. Neurobiol. Aging 2013, 34:2488-2494.
77. Heringa S.M., Reijmer Y.D., Leemans A., Koek H.L., Kappelle L.J., Biessels G.J. Utrecht Vascular Cognitive Impairment (VCI) Study Group, multiple microbleeds are related to cerebral network disruptions in patients with early Alzheimer's disease. J. Alzheimers Dis. 2014, 38:211-221.
78. Poels M.M., Ikram M.A., van der Lugt A., Hofman A., Niessen W.J., Krestin G.P., Breteler M.M., Vernooij M.W. Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study. Neurology 2012, 78:326-333.
79. Fazekas F., Kleinert R., Offenbacher H., Schmidt R., Kleinert G., Payer F., Radner H., Lechner H. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993, 43:1683-1689.
80. Brickman A.M. Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. Curr. Neurol. Neurosci. Rep. 2013, 13. (415-013-0415-7).
81. Hanaoka T., Kimura N., Aso Y., Takemaru M., Kimura Y., Ishibashi M., Matsubara E. Relationship between white matter lesions and regional cerebral blood flow changes during longitudinal follow up in Alzheimer's disease. Geriatr. Gerontol. Int. 2015.
82. Grimmer T., Faust M., Auer F., Alexopoulos P., Forstl H., Henriksen G., Perneczky R., Sorg C., Yousefi B.H., Drzezga A., Kurz A. White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol. Aging 2012, 33:2766-2773.
83. Kotrotsou A., Schneider J.A., Bennett D.A., Leurgans S.E., Dawe R.J., Boyle P.A., Golak T., Arfanakis K. Neuropathologic correlates of regional brain volumes in a community cohort of older adults. Neurobiol. Aging 2015, 36:2798-2805.
84. Dawe R.J., Bennett D.A., Schneider J.A., Leurgans S.E., Kotrotsou A., Boyle P.A., Arfanakis K. Ex vivo T2 relaxation: associations with age-related neuropathology and cognition. Neurobiol. Aging 2014, 35:1549-1561.
85. Benedictus M.R., van Harten A.C., Leeuwis A.E., Koene T., Scheltens P., Barkhof F., Prins N.D., van der Flier W.M. White matter hyperintensities relate to clinical progression in subjective cognitive decline. Stroke 2015, 46:2661-2664.
86. Bartley M., Bokde A.L., Ewers M., Faluyi Y.O., Tobin W.O., Snow A., Connolly J., Delaney C., Coughlan T., Collins D.R., Hampel H., O'Neill D. Subjective memory complaints in community dwelling healthy older people: the influence of brain and psychopathology. Int. J. Geriatr. Psychiatry 2012, 27:836-843.
87. Love S., Miners J.S. White matter hypoperfusion and damage in dementia: post-mortem assessment. Brain Pathol. 2015, 25:99-107.
88. Takeda S., Sato N., Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front. Aging Neurosci. 2014, 6:171.
89. Montagne A., Barnes S.R., Sweeney M.D., Halliday M.R., Sagare A.P., Zhao Z., Toga A.W., Jacobs R.E., Liu C.Y., Amezcua L., Harrington M.G., Chui H.C., Law M., Zlokovic B.V. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015, 85:296-302.
90. Tai L.M., Holloway K.A., Male D.K., Loughlin A.J., Romero I.A. Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J. Cell. Mol. Med. 2010, 14:1101-1112.
91. Sengillo J.D., Winkler E.A., Walker C.T., Sullivan J.S., Johnson M., Zlokovic B.V. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol. 2013, 23:303-310.
92. Ujiie M., Dickstein D.L., Carlow D.A., Jefferies W.A. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003, 10:463-470.
93. Kalaria R.N., Hedera P. Differential degeneration of the cerebral microvasculature in Alzheimer's disease. Neuroreport 1995, 6:477-480.
94. Wu M.H. Endothelial focal adhesions and barrier function. J. Physiol. 2005, 569:359-366.
95. Halliday M.R., Rege S.V., Ma Q., Zhao Z., Miller C.A., Winkler E.A., Zlokovic B.V. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J. Cereb. Blood Flow Metab. 2015.
96. Hunt A., Schonknecht P., Henze M., Seidl U., Haberkorn U., Schroder J. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. Psychiatry Res. 2007, 155:147-154.
97. Mosconi L., Tsui W.H., De Santi S., Li J., Rusinek H., Convit A., Li Y., Boppana M., de Leon M.J. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005, 64:1860-1867.
98. Starr J.M., Wardlaw J., Ferguson K., MacLullich A., Deary I.J., Marshall I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry 2003, 74:70-76.
99. Schmitz M., Hermann P., Oikonomou P., Stoeck K., Ebert E., Poliakova T., Schmidt C., Llorens F., Zafar S., Zerr I. Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy. Neurobiol. Aging 2015, 36:2597-2606.
100. Iadecola C., Nedergaard M. Glial regulation of the cerebral microvasculature. Nat. Neurosci. 2007, 10:1369-1376.
101. Rombouts S.A., Barkhof F., Goekoop R., Stam C.J., Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum. Brain Mapp. 2005, 26:231-239.
102. Ruitenberg A., den Heijer T., Bakker S.L., van Swieten J.C., Koudstaal P.J., Hofman A., Breteler M.M. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann. Neurol. 2005, 57:789-794.
103. Shim Y., Yoon B., Shim D.S., Kim W., An J.Y., Yang D.W. Cognitive correlates of cerebral vasoreactivity on transcranial Doppler in older adults. J. Stroke Cerebrovasc. Dis. 2015, 24:1262-1269.
104. Kalback W., Esh C., Castano E.M., Rahman A., Kokjohn T., Luehrs D.C., Sue L., Cisneros R., Gerber F., Richardson C., Bohrmann B., Walker D.G., Beach T.G., Roher A.E. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol. Res. 2004, 26:525-539.
105. McDade E., Kim A., James J., Sheu L.K., Kuan D.C., Minhas D., Gianaros P.J., Ikonomovic S., Lopez O., Snitz B., Price J., Becker J., Mathis C., Klunk W. Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease. Neurology 2014, 83:710-717.
106. Miners J.S., Palmer J.C., Love S. Pathophysiology of hypoperfusion of the precuneus in early Alzheimer's disease. Brain Pathol. 2015.
107. Yu L., Boyle P.A., Leurgans S., Schneider J.A., Kryscio R.J., Wilson R.S., Bennett D.A. Effect of common neuropathologies on progression of late life cognitive impairment. Neurobiol. Aging 2015, 36:2225-2231.
108. Troncoso J.C., Zonderman A.B., Resnick S.M., Crain B., Pletnikova O., O'Brien R.J. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann. Neurol. 2008, 64:168-176.
109. Nag S., Yu L., Capuano A.W., Wilson R.S., Leurgans S.E., Bennett D.A., Schneider J.A. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann. Neurol. 2015, 77:942-952.
110. Rahimi J., Kovacs G.G. Prevalence of mixed pathologies in the aging brain. Alzheimers Res. Ther. 2014, 6. (82-014-0082-1. eCollection 2014).
111. Neltner J.H., Abner E.L., Baker S., Schmitt F.A., Kryscio R.J., Jicha G.A., Smith C.D., Hammack E., Kukull W.A., Brenowitz W.D., Van Eldik L.J., Nelson P.T. Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain 2014, 137:255-267.
112. Dugger B.N., Adler C.H., Shill H.A., Caviness J., Jacobson S., Driver-Dunckley E., Beach T.G. Arizona Parkinson's Disease Consortium, concomitant pathologies among a spectrum of Parkinsonian disorders. Parkinsonism Relat. Disord. 2014, 20:525-529.
113. Buchman A.S., Leurgans S.E., Nag S., Bennett D.A., Schneider J.A. Cerebrovascular disease pathology and Parkinsonian signs in old age. Stroke 2011, 42:3183-3189.
114. de Flores R., La Joie R., Chetelat G. Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease. Neuroscience 2015.
115. McGeer P.L., Kamo H., Harrop R., McGeer E.G., Martin W.R., Pate B.D., Li D.K. Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease. Neurology 1986, 36:1569-1574.
116. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
117. Albin R.L., Koeppe R.A., Burke J.F., Giordani B., Kilbourn M.R., Gilman S., Frey K.A. Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment. Arch. Neurol. 2010, 67:440-446.
118. Blennow M., Ingvar M., Lagercrantz H., Stone-Elander S., Eriksson L., Forssberg H., Ericson K., Flodmark O. Early [18F]FDG positron emission tomography in infants with hypoxic-ischaemic encephalopathy shows hypermetabolism during the postasphyctic period. Acta Paediatr. 1995, 84:1289-1295.
119. Bunevicius A., Yuan H., Lin W. The potential roles of 18F-FDG-PET in management of acute stroke patients. Biomed. Res. Int. 2013, 2013:634598.
120. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
121. Yang L., Rieves D., Ganley C. Brain amyloid imaging-FDA approval of florbetapir F18 injection. N. Engl. J. Med. 2012, 367:885-887.
122. Jack C.R., Wiste H.J., Lesnick T.G., Weigand S.D., Knopman D.S., Vemuri P., Pankratz V.S., Senjem M.L., Gunter J.L., Mielke M.M., Lowe V.J., Boeve B.F., Petersen R.C. Brain beta-amyloid load approaches a plateau. Neurology 2013, 80:890-896.
123. Dani M., Edison P., Brooks D.J. Imaging biomarkers in tauopathies. Parkinsonism Relat. Disord. 2015.
124. Dugger B.N., Clark C.M., Serrano G., Mariner M., Bedell B.J., Coleman R.E., Doraiswamy P.M., Lu M., Fleisher A.S., Reiman E.M., Sabbagh M.N., Sadowsky C.H., Schneider J.A., Zehntner S.P., Carpenter A.P., Joshi A.D., Mintun M.A., Pontecorvo M.J., Skovronsky D.M., Sue L.I., Beach T.G. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J. Neuropathol. Exp. Neurol. 2014, 73:72-80.
125. Peca S., McCreary C.R., Donaldson E., Kumarpillai G., Shobha N., Sanchez K., Charlton A., Steinback C.D., Beaudin A.E., Fluck D., Pillay N., Fick G.H., Poulin M.J., Frayne R., Goodyear B.G., Smith E.E. Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy. Neurology 2013, 81:1659-1665.
126. Sweeney M.D., Sagare A.P., Zlokovic B.V. Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease. J. Cereb. Blood Flow Metab. 2015, 35:1055-1068.
127. Brinkmalm A., Portelius E., Ohrfelt A., Brinkmalm G., Andreasson U., Gobom J., Blennow K., Zetterberg H. Explorative and targeted neuroproteomics in Alzheimer's disease. Biochim. Biophys. Acta 2015, 1854:769-778.